VIDEO: No improvement in colon cancer ctDNA clearance after adjuvant chemotherapy
Click Here to Manage Email Alerts
In this video, Afsaneh Barzi, MD, PhD, discussed the phase 2 results from the NRG-GI005 (COBRA) study.
The study, presented at ASCO Gastrointestinal Cancers Symposium, examined the role of circulating tumor DNA (ctDNA) in directing adjuvant chemotherapy for patients with stage II colon cancer.
Patients who received adjuvant chemotherapy experienced no improvement in ctDNA clearance after 6 months of treatment.
“In my opinion, this was an emphasis that ctDNA and [minimal residual disease (MRD)] at this time point should be restricted to the clinical trial, and we really should not use, or be very judicious in using this assay and data in making clinical decision in our day-to-day practice,” Barzi, a medical oncologist at City of Hope, said.
Reference:
- Morris VK, et al. Abstract 5. Presented at: ASCO Gastrointestinal Cancers Symposium; Jan. 18-20, 2024; San Francisco.
Collapse
Healio Interviews
Click Here to Manage Email Alerts